Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted delivery of lipid nanoparticles (LNPs) across the BBB using peptide or single-domain antibody (sdAb) vectors.
The results demonstrate enhanced transfection of brain and spinal cord cells an also the precise distribution of LNPs within distinct CNS compartments, including the microvasculature, extracellular fluid (ECF), and parenchyma.
The data underline the capability of this platform to overcome longstanding challenges in CNS-targeted mRNA therapeutics. By enabling precise delivery to challenging targets like the CNS and spinal cord, VECTrans® opens new avenues for treating neurological disorders as well as other diseases requiring targeted and efficient delivery systems.